ArticleBMC cancer2026
PD-L1 copy number loss is associated with lower survival in women with advanced breast cancer in Indonesian cohort.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognostic value of PD-L1 copy number variation (CNV) in advanced breast cancer (BC) patients remains unclear. This study investigated the association between PD-L1 CNV and its prognostic significance in advanced BC.
methodsPD-L1 CNV was analyzed using real-time PCR in advanced BC patients (n = 132) who received chemotherapy or hormonal therapy, along with a non-malignant control group (n = 5) obtained from patients with histopathologically confirmed fibroadenoma used as reference controls. The association of PD-L1 CNV with overall survival and clinicopathological features was determined.
resultsPD-L1 CNVs were identified in 22% (29/132) of advanced BC cases, comprising 9 CN losses and 20 CN gains. PDL-1 CN loss was associated with low overall survival (OS) (HR = 2.61; 95% CI = 1.10-6.21; p = 0.024) and remained significant after multivariate adjustment (HR = 3.13; 95% CI = 1.23-7.94; p = 0.016). The adverse prognostic effect was pronounced in HR-positive (p = 0.004) and HER2-negative patients (p = 0.040). PD-L1 CNVs were more frequent in patients > 40 years (p = 0.027) and HER2-negative tumors (p = 0.019).
conclusionsPD-L1 CN loss was associated with lower OS, particularly in HR(+) and HER2(-) patients. This result revealed the prognostic value of PD-L1 CNV in Indonesian advanced BC who received primary systemic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.